Sign up Australia
Proactive Investors - Run By Investors For Investors
Why invest in DXB?
Dimerix Ltd: THE INVESTMENT CASE

Dimerix: Access latest PPT from Proactive's CEO Sessions

Kathy Harrison talked pending milestone news with investors.
Dimerix: Access latest PPT from Proactive's CEO Sessions
INVESTMENT OVERVIEW: DXB The Big Picture
Kathy Harrison, CEO, Dimerix

Dimerix’ (ASX:DXB) chief executive officer, Kathy Harrison, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.

The company will have milestone news flow in coming months from its Phase II clinical trials for chronic kidney disease.

The company's lead clinical program, DMX 200, has been granted Orphan Drug Designation status in the U.S. for a medical condition called Focal Segmental Glomerulosclerosis (FSGS).

The innovative treatment combines two existing drugs.


ACCESS THE FULL PRESENTATION HERE





Register here to be notified of future DXB Company articles
View full DXB profile View Profile

Dimerix Ltd Timeline

Newswire
January 23 2017

Related Articles

generic pill and bottle shot to denote Alliance's products
August 14 2017
The company has made the transition from a business capitalised at £90mln to company now worth around a quarter of a billion pounds - but has the market at large picked up on (and priced in) the transformation?
picture of drug researcher
July 19 2017
Enlarged company can become an emerging leader in the application of gene modulation technologies
"Cancer" in bold
July 28 2017
Undoubtedly the highlight was the successful completion of US and European studies evaluating over 400 patients using the company’s Parsortix system

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use